Международное проспективное открытое рандомизированное исследование фазы III, сравнивающее 177Lu-PSMA-617 в комбинации с SoC по сравнению с монотерапией SoC у взрослых пациентов мужского пола с mHSPC (PSMAddition)
Открытое рандомизированное исследование III фазы, в котором сравнивали 177Lu-PSMA-617 в комбинации со стандартной терапией по сравнению со стандартной терапией отдельно у взрослых пациентов мужского пола с метастатическим гормоночувствительным раком предстательной железы (mHSPC)
The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care (SOC), versus Standard of Care alone, in adult male patients with Metastatic hormone sensitive prostate cancer (mHSPC). In this study, the SoC is defined as a combination of Androgen Receptor Directed Therapy (ARDT) + Androgen Deprivation Therapy (ADT). Approximately 1126 patients will be randomized in this study. As of 31-Jan-2024, 1144 participants were enrolled in 19 countries.
Обзор исследования
Статус
Статус
Условия
Условия
Вмешательство/лечение
Вмешательство/лечение
Подробное описание
In this international, open-label, prospective, phase III study, where approximately 1126 patients with treatment naïve or minimally treated PSMA-positive mHSPC were to be randomized in a 1:1 ratio to receive Standard of Care (SoC) with or without the radioligand 177Lu-PSMA-617.
The primary objective of the study was to determine whether the combination of 177Lu-PSMA-617 + SoC improved radiographic progression free survival (rPFS) over that obtained by administration of SoC alone in mHSPC patients.
The randomization was stratified according to the following three factors: disease volume (high v low), age >= 70 years (yes/no), and on Previous or planned treatment (prostatectomy or radiation) to primary (prostate) tumor (yes/no).
Planned study duration: approximately 50 months. screening period: after signing ICF, patients were assessed for eligibility and were scanned with 68Ga PSMA-11 to identify PSMA expression status. Following completion of all required screening procedures and verifying participant eligibility, the participant was randomized via the interactive response technology (IRT) system.
Amended protocol v02 included an option for participants to be enrolled into a separate long-term safety follow-up study, and China extension cohort (40 to 60 participants). Amended protocol v03 excluded China extension cohort and added a second 68Ga-PSMA-11 PET/CT scan at Radiographic progressive disease (rPD) following Blind Independent Review Committee (BIRC) confirmed rPD in both arms.
Prior treatment:
- Up to 45 days of Luteinizing hormone releasing hormone (LHRH) agonist/antagonists was allowed prior to informed consent form (ICF) signature. If patient did not start the ADT prior randomization, ADT started as soon as possible and ideally no later than 2 weeks after randomization.
- Up to 45 days of ARDT was allowed prior ICF signature. If patient did not start the ARDT prior randomization, ARDT started as soon as possible and ideally no later than 2 weeks after randomization. Patients received ARDT as per label instructions.
Randomization period:
The participant was randomized in a 1:1 ratio to receive Standard of Care (SoC) with or without the radioligand 177Lu-PSMA-617.
Treatment period:
Patients randomized to the investigational arm (i.e. SoC+177Lu-PSMA-617): Patients received SoC as per label instructions, after randomization, if not started earlier and in the time frame allowed by the protocol. Patients began 177Lu-PSMA-617 dosing within 14 days after randomization or as soon as possible after the product was received. 177Lu-PSMA-617 is administered at the dose of 7.4 GBq (+/- 10%), once every 6 weeks (+/- 1 week) for a planned 6 cycles.
Patients randomized to the control arm began receiving SoC as per label instructions after randomization, if not started earlier and in the time frame allowed by the protocol.
The primary endpoint of rPFS was assessed by a centralized blinded image review committee (i.e., BIRC) using radiographic images provided by the treating physician.
Participants from both arms also underwent PET/CT scan with 68GaPSMA-11 following Centrally confirmed rPD.
An end of treatment (EOT) visit will be performed when participants permanently discontinue study treatment.
Cross-over period:
After patients randomized to the SoC alone (i.e., control) arm experience radiographic progression (the rPFS event) as confirmed by BIRC, they will be allowed to cross-over to receive 177Lu-PSMA-617 +/- SoC per the discretion of the treating physician. If cross-over to 177Lu-PSMA-617 is selected, then 177Lu-PSMA-617 will be administered with the same dose/schedule as participants who were initially randomized to receive 177Lu-PSMA-617 as described above. Study cross-over participants for whom 177Lu-PSMA-617 is discontinued must have a second End of Treatment (EOT2) visit performed =< 7 days and enter the Post-treatment Follow-up.
Post-Treatment Follow-Up (Safety, Efficacy):
After treatment discontinuation, all participants will be followed for safety with a 30-day safety follow-up visit (FUP) as well as longer term safety follow-up assessments for a period of approximately 12 months.
Participants who discontinue study treatment without having progressive disease confirmed by BIRC, will continue to be assessed for efficacy (efficacy follow-up) during the post-treatment follow-up period until the occurrence of their BIRC-confirmed radiographic disease progression (rPFS) event , or if the total number of protocol-defined rPFS events has occurred triggering the primary analysis, whichever occurs first.
Survival Follow-Up:
After study treatment discontinuation, or post-treatment follow-up period discontinuation, the participant's status will be collected every 90 days (via phone calls) as part of the survival follow-up. Every effort should be made to comply with the survival follow-up schedule and ensure collection of participant survival. The survival follow-up and the study will end when the number of OS events required for final OS analysis will be reached.
Тип исследования
Тип исследования
Регистрация (Действительный)
Регистрация
Фаза
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
-
Linz, Австрия, 4020
- Novartis Investigative Site
-
Vienna, Австрия, 1090
- Novartis Investigative Site
-
-
Tyrol
-
Innsbruck, Tyrol, Австрия, 6020
- Novartis Investigative Site
-
-
-
-
-
Brussels, Бельгия, 1200
- Novartis Investigative Site
-
Ghent, Бельгия, 9000
- Novartis Investigative Site
-
-
-
-
-
Essen, Германия, 45147
- Novartis Investigative Site
-
München, Германия, 80377
- Novartis Investigative Site
-
Münster, Германия, 48149
- Novartis Investigative Site
-
Rostock, Германия, 18057
- Novartis Investigative Site
-
-
Bavaria
-
Würzburg, Bavaria, Германия, 97080
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Германия, 50937
- Novartis Investigative Site
-
-
-
-
-
Copenhagen, Дания, 2100
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Испания, 08035
- Novartis Investigative Site
-
Barcelona, Испания, 08036
- Novartis Investigative Site
-
Madrid, Испания, 28041
- Novartis Investigative Site
-
Madrid, Испания, 28034
- Novartis Investigative Site
-
Madrid, Испания, 28046
- Novartis Investigative Site
-
Madrid, Испания, 28040
- Novartis Investigative Site
-
Madrid, Испания, 28222
- Novartis Investigative Site
-
Valencia, Испания, 46026
- Novartis Investigative Site
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Испания, 08907
- Novartis Investigative Site
-
Sabadell, Barcelona, Испания, 08208
- Novartis Investigative Site
-
-
Murcia
-
El Palmar, Murcia, Испания, 30120
- Novartis Investigative Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Канада, V5Z 1M9
- Novartis Investigative Site
-
-
Ontario
-
Hamilton, Ontario, Канада, L8V 5C2
- Novartis Investigative Site
-
Toronto, Ontario, Канада, M4N 3M5
- Novartis Investigative Site
-
-
Quebec
-
Montreal, Quebec, Канада, H4A 3J1
- Novartis Investigative Site
-
Montreal, Quebec, Канада, H3T 1E2
- Novartis Investigative Site
-
Montreal, Quebec, Канада, H2X 1R9
- Novartis Investigative Site
-
Québec, Quebec, Канада, G1R 2J6
- Novartis Investigative Site
-
Sherbrooke, Quebec, Канада, J1H 5N4
- Novartis Investigative Site
-
-
-
-
-
Beijing, Китай, 100036
- Novartis Investigative Site
-
Guangzhou, Китай, 510060
- Novartis Investigative Site
-
Shanghai, Китай, 200080
- Novartis Investigative Site
-
Shanghai, Китай, 200032
- Novartis Investigative Site
-
Shanghai, Китай, 200025
- Novartis Investigative Site
-
Tianjin, Китай, 300300
- Novartis Investigative Site
-
-
Jiangsu
-
Nanjing, Jiangsu, Китай, 210029
- Novartis Investigative Site
-
Nanjing, Jiangsu, Китай, 210006
- Novartis Investigative Site
-
-
Shanxi
-
Xian, Shanxi, Китай, 710032
- Novartis Investigative Site
-
-
Sichuan
-
Chengdu, Sichuan, Китай, 610041
- Novartis Investigative Site
-
-
-
-
-
Nijmegen, Нидерланды, 6525 GA
- Novartis Investigative Site
-
Utrecht, Нидерланды, 3584 CX
- Novartis Investigative Site
-
-
Limburg
-
Maastricht, Limburg, Нидерланды, 6229 HX
- Novartis Investigative Site
-
-
South Holland
-
Delft, South Holland, Нидерланды, 2625 AD
- Novartis Investigative Site
-
-
-
-
-
Krakow, Польша, 30-688
- Novartis Investigative Site
-
Warsaw, Польша, 02-781
- Novartis Investigative Site
-
-
Silesian Voivodeship
-
Gliwice, Silesian Voivodeship, Польша, 44-101
- Novartis Investigative Site
-
-
-
-
-
Singapore, Сингапур, 119228
- Novartis Investigative Site
-
Singapore, Сингапур, 168583
- Novartis Investigative Site
-
-
-
-
-
Belfast, Соединенное Королевство, BT9 7AB
- Novartis Investigative Site
-
Cambridge, Соединенное Королевство, CB2 0QQ
- Novartis Investigative Site
-
Glasgow, Соединенное Королевство, G12 0YN
- Novartis Investigative Site
-
London, Соединенное Королевство, NW3 2QG
- Novartis Investigative Site
-
London, Соединенное Королевство, EC1A 7BE
- Novartis Investigative Site
-
London, Соединенное Королевство, NW1 2BU
- Novartis Investigative Site
-
Middlesbrough, Соединенное Королевство, TS4 3BW
- Novartis Investigative Site
-
-
Surrey
-
Sutton, Surrey, Соединенное Королевство, SM2 5PT
- Novartis Investigative Site
-
-
-
-
Arizona
-
Scottsdale, Arizona, Соединенные Штаты, 85259
- Mayo Clinic Arizona
-
-
California
-
La Jolla, California, Соединенные Штаты, 92093-0658
- University of California San Diego - Moores Cancer Center
-
Los Angeles, California, Соединенные Штаты, 90073
- VA Greater LA Healthcare System
-
Los Angeles, California, Соединенные Штаты, 90095
- University of California LA
-
Orange, California, Соединенные Штаты, 92868
- Univ Cali Irvine ALS Neuromuscular
-
Orange, California, Соединенные Штаты, 92686
- St. Joseph Hospital
-
Palo Alto, California, Соединенные Штаты, 94304
- Stanford University Medical Center
-
Palo Alto, California, Соединенные Штаты, 94304-1207
- VA Palo Alto Health Care System
-
Santa Barbara, California, Соединенные Штаты, 93105
- Sansum Clinic
-
Santa Monica, California, Соединенные Штаты, 90404
- Providence Saint Johns Health Ctr
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80045
- Univ Of Color Anschutz Med Center
-
Denver, Colorado, Соединенные Штаты, 80218
- Rocky Mountain Cancer Centers
-
-
Connecticut
-
Hartford, Connecticut, Соединенные Штаты, 06102
- Hartford Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Соединенные Штаты, 20007
- Georgetown University-Lombardi Cancer Center
-
Washington D.C., District of Columbia, Соединенные Штаты, 20422
- VA Medical Center
-
-
Florida
-
Jacksonville, Florida, Соединенные Штаты, 32256
- Cancer Specialists of North Florida
-
Jacksonville, Florida, Соединенные Штаты, 32224
- Mayo Clinic Jacksonville
-
Miami, Florida, Соединенные Штаты, 33173
- Baptist Health South
-
Miami, Florida, Соединенные Штаты, 33136
- University Of Miami
-
Panama City, Florida, Соединенные Штаты, 32405
- Florida Cancer Affiliates
-
-
Georgia
-
Athens, Georgia, Соединенные Штаты, 30607
- University Cancer and Blood Center LLC
-
-
Hawaii
-
Honolulu, Hawaii, Соединенные Штаты, 96813
- The Queens Medical Centre
-
-
Illinois
-
Chicago, Illinois, Соединенные Штаты, 60611
- Northwestern University
-
Chicago, Illinois, Соединенные Штаты, 60612
- Rush University Medical Center
-
Chicago, Illinois, Соединенные Штаты, 60637
- University of Chicago
-
Hines, Illinois, Соединенные Штаты, 60141
- Hines VA Hospital
-
-
Indiana
-
Fort Wayne, Indiana, Соединенные Штаты, 46845
- Parkview Research Center
-
Indianapolis, Indiana, Соединенные Штаты, 46202
- Indiana University
-
-
Louisiana
-
New Orleans, Louisiana, Соединенные Штаты, 70121
- Ochsner Clinic Foundation
-
New Orleans, Louisiana, Соединенные Штаты, 70112
- Tulane Cancer Center
-
-
Maryland
-
Baltimore, Maryland, Соединенные Штаты, 21231
- Sidney Kimmel CCC At JH
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02115
- Dana Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, Соединенные Штаты, 48109
- Uni Of Michigan Health System
-
Royal Oak, Michigan, Соединенные Штаты, 48073-6769
- Corewell Health William Beaum Hosp
-
-
Minnesota
-
Minneapolis, Minnesota, Соединенные Штаты, 55455
- University of Minnesota
-
Rochester, Minnesota, Соединенные Штаты, 55905
- Mayo Clinic Rochester
-
-
Mississippi
-
Jackson, Mississippi, Соединенные Штаты, 39216
- University of Mississippi Med Ctr
-
-
Missouri
-
St Louis, Missouri, Соединенные Штаты, 63106
- VA St Louis Health Care System
-
St Louis, Missouri, Соединенные Штаты, 63110
- Wash U School of Medicine
-
St Louis, Missouri, Соединенные Штаты, 63104
- St Louis University
-
-
Nebraska
-
Omaha, Nebraska, Соединенные Штаты, 68130
- Urology Cancer Center PC
-
Omaha, Nebraska, Соединенные Штаты, 68130
- Nebraska Cancer Specialists
-
-
New Mexico
-
Albuquerque, New Mexico, Соединенные Штаты, 87131-0001
- University of New Mexico
-
-
New York
-
New York, New York, Соединенные Штаты, 10021
- Weill Cornell Medical College
-
New York, New York, Соединенные Штаты, 10065
- Memorial Sloan Kettering Cancer Ctr
-
Rochester, New York, Соединенные Штаты, 14642
- Univ Of Rochester Cancer Ctr
-
The Bronx, New York, Соединенные Штаты, 10467
- Montefiore Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, Соединенные Штаты, 28203
- Levine Cancer Institute
-
Durham, North Carolina, Соединенные Штаты, 27710
- Duke Univ Medical Center
-
-
Ohio
-
Cleveland, Ohio, Соединенные Штаты, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, Соединенные Штаты, 43221
- The Ohio State University Comprehensive Cancer Center
-
-
Oregon
-
Portland, Oregon, Соединенные Штаты, 97239
- Oregon Health Sciences University
-
-
Pennsylvania
-
Hershey, Pennsylvania, Соединенные Штаты, 17033
- Penn State Hershey Medical Center
-
Philadelphia, Pennsylvania, Соединенные Штаты, 19107
- Thomas Jefferson Univ Hosp
-
Pittsburgh, Pennsylvania, Соединенные Штаты, 15232
- Univ of Pittsburgh Cancer Institute
-
-
South Carolina
-
Myrtle Beach, South Carolina, Соединенные Штаты, 29572
- Carolina Urologic Research Center
-
-
Texas
-
Amarillo, Texas, Соединенные Штаты, 79124
- Texas Oncology
-
Dallas, Texas, Соединенные Штаты, 75216
- Dallas VA Medical Center
-
Dallas, Texas, Соединенные Штаты, 75390-9034
- Univ of Texas Southwest Med Center
-
Houston, Texas, Соединенные Штаты, 77030
- MD Anderson
-
Houston, Texas, Соединенные Штаты, 77030
- UT Health Science Center
-
San Antonio, Texas, Соединенные Штаты, 78229
- UT Health San Antonio Mays Cancer Center
-
-
Virginia
-
Charlottesville, Virginia, Соединенные Штаты, 22908
- University of Virginia Medical Center
-
Norfolk, Virginia, Соединенные Штаты, 23502
- Virginia Oncology Associates
-
Roanoke, Virginia, Соединенные Штаты, 24014
- Onco Hemato Asso of SW Virginia
-
-
Washington
-
Seattle, Washington, Соединенные Штаты, 98122-4379
- Swedish Medical Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Соединенные Штаты, 53226
- Medical College of Wisconsin
-
-
-
-
-
Taipei, Тайвань, 10002
- Novartis Investigative Site
-
Taoyuan, Тайвань, 33305
- Novartis Investigative Site
-
-
-
-
-
Bordeaux, Франция, 33075
- Novartis Investigative Site
-
Clermont-Ferrand, Франция, 63011
- Novartis Investigative Site
-
Lyon, Франция, 69373
- Novartis Investigative Site
-
Montpellier, Франция, 34298
- Novartis Investigative Site
-
Nantes, Франция, 44093
- Novartis Investigative Site
-
Paris, Франция, 75015
- Novartis Investigative Site
-
Paris, Франция, 75018
- Novartis Investigative Site
-
Strasbourg, Франция, 67000
- Novartis Investigative Site
-
Vandœuvre-lès-Nancy, Франция, 54511
- Novartis Investigative Site
-
Villejuif, Франция, 94800
- Novartis Investigative Site
-
-
-
-
-
Olomouc, Чехия, 779 00
- Novartis Investigative Site
-
Prague, Чехия, 150 06
- Novartis Investigative Site
-
-
-
-
-
Bern, Швейцария, 3010
- Novartis Investigative Site
-
Lausanne, Швейцария, 1011
- Novartis Investigative Site
-
-
-
-
-
Gothenburg, Швеция, 413 45
- Novartis Investigative Site
-
Lund, Швеция, 221 85
- Novartis Investigative Site
-
Stockholm, Швеция, 17176
- Novartis Investigative Site
-
-
-
-
-
Seoul, Южная Корея, 03080
- Novartis Investigative Site
-
Seoul, Южная Корея, 05505
- Novartis Investigative Site
-
Seoul, Южная Корея, 03722
- Novartis Investigative Site
-
-
-
-
-
Chiba, Япония, 2608717
- Novartis Investigative Site
-
Fukuoka, Япония, 8128582
- Novartis Investigative Site
-
Fukuoka, Япония, 8110213
- Novartis Investigative Site
-
Fukuoka, Япония, 8120033
- Novartis Investigative Site
-
Fukushima, Япония, 9601295
- Novartis Investigative Site
-
Kyoto, Япония, 6068507
- Novartis Investigative Site
-
Okayama, Япония, 7008558
- Novartis Investigative Site
-
Yamagata, Япония, 9909585
- Novartis Investigative Site
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Япония, 4668560
- Novartis Investigative Site
-
-
Hokkaido
-
Sapporo, Hokkaido, Япония, 0608648
- Novartis Investigative Site
-
-
Hyōgo
-
Kobe, Hyōgo, Япония, 6500047
- Novartis Investigative Site
-
-
Kanagawa
-
Yokohama, Kanagawa, Япония, 2360004
- Novartis Investigative Site
-
-
Kumamoto
-
Kumamoto, Kumamoto, Япония, 8608556
- Novartis Investigative Site
-
-
Osaka
-
Suita, Osaka, Япония, 5650871
- Novartis Investigative Site
-
-
Saitama
-
Kitaadachi-gun, Saitama, Япония, 3620806
- Novartis Investigative Site
-
-
Tokyo
-
Bunkyo Ku, Tokyo, Япония, 1138431
- Novartis Investigative Site
-
Chuo Ku, Tokyo, Япония, 1040045
- Novartis Investigative Site
-
-
Критерии участия
Критерии приемлемости
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
Participants eligible for inclusion in this study must meet all of the following criteria:
-
Signed informed consent must be obtained prior to participation in the study
-
Patients must be adults ≥18 years of age
-
Patients must have an ECOG performance status of 0 to 2
-
Patients must have a life expectancy >9 months as determined by the study investigator
-
Patients must have metastatic prostate cancer with histologically or cytologically confirmed adenocarcinoma (current or prior biopsy of the prostate and/or metastatic site)
-
Patients must have evidence of PSMA-positive disease as seen on a 68Ga-PSMA-11 PET/CT scan, and eligible as determined by the sponsor's central reader
-
Patients must have at least one documented metastatic bone and/or soft tissue/visceral lesion documented in the following manners within 28 days prior randomization:
- Metastatic disease to the bone (in any distribution) visible on 99Tc-MDP bone scintigraphy on either pre-ADT scans or baseline scans AND/OR
- Lymph node metastases of any size or distribution. If lymph nodes are the only site of metastasis, then at least one must be at least 1.5 cm in short axis AND outside of the pelvis AND/OR
- Visceral metastases of any size or distribution. If a participant has a history of visceral metastases at any time prior to randomization, he should be coded as having visceral metastases at baseline (i.e., patients with visceral metastases prior to ADT that disappear at baseline will be counted as having visceral metastases and would therefore have high volume disease for stratification purposes).
-
Patients must have adequate organ function:
- Bone marrow reserve ANC ≥1.5 x 109/L Platelets ≥100 x 109/L Hemoglobin ≥9 g/dL
- Hepatic Total bilirubin ≤2 x the institutional upper limit of normal (ULN). For patients with known Gilbert's Syndrome ≤3 x ULN is permitted Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤3.0 x ULN OR ≤5.0 x ULN for patients with liver metastases
- Renal eGFR ≥ 50 mL/min/1.73m2 using the Modification of Diet in Renal Disease (MDRD) equation
-
Albumin ≥2.5 g/dL
-
Human immunodeficiency virus (HIV)-infected patients who are healthy and have a low risk of acquired immune deficiency syndrome (AIDS)-related outcomes can participate in this trial
-
Patients must be:
Treatment naïve OR minimally treated with:
- Up to 45 days of luteinizing hormone-releasing hormone (LHRH) agonist /antagonists or bilateral orchiectomy with or without first generation anti-androgen (e.g. bicalutamide, flutamide) for metastatic prostate cancer is allowed prior to ICF signature. If given, first generation anti-androgen must be discontinued prior to start of study therapy or after 45 days whatever happens first.
- If received, prior LHRH agonist/antagonist with or without first generation anti-androgen use in the adjuvant/neo-adjuvant setting must have been discontinued > 12 months prior to ICF signature AND must not have exceeded 24 months of therapy AND must not have shown disease progression within 12 months of completing adjuvant/neo-adjuvant therapy.
- Up to 45 days of CYP17 inhibitor or ARDT exposure for metastatic prostate cancer is allowed prior to ICF signature. No CYP17 inhibitor or ARDT exposure for earlier stages of prostate cancer is allowed.
Exclusion Criteria:
Participants meeting any of the following criteria are not eligible for inclusion in this study.
-
Participants with rapidly progressing tumor that requires urgent exposure to taxane-based chemotherapy
-
Any prior systemic anti-prostate cancer therapy (with the exception of the drugs listed on inclusion criteria 11), including chemotherapy, Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors, immunotherapy or biological therapy (including monoclonal antibodies).
-
Concurrent cytotoxicity chemotherapy, immunotherapy, radioligand therapy, PARP inhibitor, biological therapy or investigational therapy
-
Previous treatment with any of the following within 6 months of randomization: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation. Previous PSMA-targeted radioligand therapy is not allowed
-
Ongoing participation in any other clinical trial
-
Use of other investigational drugs within 30 days prior to day of randomization
-
Known hypersensitivity to any of the study treatments or its excipients or to drugs of similar chemical classes
-
Transfusion for the sole purpose of making a participant eligible for study inclusion
-
Participants with CNS metastases that are neurologically unstable, symptomatic, or receiving corticosteroids for the purpose of maintaining neurologic integrity. Participants with epidural disease, canal disease and prior cord involvement are allowed if those areas have been treated, are stable, and not neurologically impaired. Participants with parenchymal CNS metastasis (or a history of CNS metastasis), that have received prior therapy and are neurologically stable, asymptomatic and not receiving steroids for CNS metastases, are allowed, baseline and subsequent radiological imaging must include evaluation of the brain (magnetic resonance imaging (MRI) preferred or CT with contrast).
-
Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, participants with a prior history of malignancy that has been adequately treated and who have been disease free, treatment free for more than 3 years prior to randomization, or participants with adequately treated non-melanoma skin cancer, superficial bladder cancer are eligible.
-
Concurrent serious (as determined by the Principal Investigator) medical conditions, including, but not limited to, uncontrolled infection, known active hepatitis B or C, or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation. Participants with an active documented COVID-19 infection (any grade of disease severity) at time of informed consent may be included only when completely recovered (in accordance with local guidance).
-
Active clinically significant cardiac disease defined as any of the following:
- NYHA class 3/4 congestive heart failure within 6 months prior to ICF signature unless treated with improvement and echocardiogram or MUGA demonstrates EF > 45% with improvement in symptoms to class < 3.
- History or current diagnosis of ECG abnormalities indicating significant risk of safety for participants in the study such as: Concomitant clinically significant cardiac arrhythmias, e.g. sustained ventricular tachycardia, complete left bundle branch block, high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II and third degree AV block)
- History of familial long QT syndrome or known family history of Torsades de Pointes
- Cardiac or cardiac repolarization abnormality, including any of the following: History of myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to ICF signature
-
History of somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study
-
Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression
-
Inability to complete the study imaging procedures due to any reason (e.g., severe claustrophobia, inability to lie still for the entire imaging time, any condition that precludes raised arms position)
-
Unmanageable concurrent bladder outflow obstruction or urinary incontinence. Note: participants with bladder outflow obstruction or urinary incontinence, which is manageable and controlled with best available standard of care (incl. pads, drainage) are allowed.
-
Sexually active males unwilling to use a condom during intercourse while taking study treatment and for 14 weeks after stopping study treatment. A condom is required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of study treatment via seminal fluid to their partner. In addition, male participants must not donate sperm for the time period specified above. If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the ICF
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Количество рук
Оружие и интервенции
Группа участников / АрмияГруппа участников / Армия |
Вмешательство/лечениеВмешательство/лечение |
|---|---|
|
Экспериментальный: 177Lu-PSMA-617 + SoC
Participant will receive 7.4 GBq (+/- 10%) 177Lu-PSMA-617, once every 6 weeks (+/- 1 week) for a planned 6 cycles, in addition to the Standard of Care (SOC); Androgen receptor-directed therapy (ARDT) + Androgen deprivation therapy (ADT) is considered as SOC and treatment will be administered per the physician's order |
administered intravenously once every 6 weeks (1 cycle) for 6 cycles
Другие имена:
Intravenous dose of approx. 150 Megabecquerel (MBq) at screening and at time of centrally confirmed rPD
Другие имена:
Administered orally on a continuous basis as per package insert and guideline ADT are administered as per physician order |
|
Активный компаратор: Standard of Care (SOC)
For participants randomized to Standard of Care arm, ARDT +ADT is considered as SOC and treatment will be administered per the physician's order |
Intravenous dose of approx. 150 Megabecquerel (MBq) at screening and at time of centrally confirmed rPD
Другие имена:
Administered orally on a continuous basis as per package insert and guideline ADT are administered as per physician order |
Что измеряет исследование?
Первичные показатели результатов
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Radiographic Progression Free Survival (rPFS)
Временное ограничение: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approx 43 months
|
rPFS is defined as the time of radiographic progression by Prostate Cancer Working Group 3 (PCWG3)-modified RECIST V1.1 as assessed by blinded independent central review (BIRC), or death from any cause whichever occurs first. Radiographic progression was determined by: progression in soft tissue, using RECIST 1.1 with modification outlined in PCWG3 or progression in bone disease, using bone scan and the 2+2 rule defined in the PCWG3: Rule 1 progression defined as at least 2 new lesions on first scan at week 12 and confirmed 12 weeks after with the 2 or more new lesions seen on first scan at week 12 that persist on next scan and with at least 2 additional lesions; Rule 2 progression (at week 24 or later confirmed at next scan) defined as at least 2 new lesions relative to the baseline scan observed for scans after the 18 weeks flare window, and confirmed on a subsequent scan. |
From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approx 43 months
|
Вторичные показатели результатов
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Overall Survival (OS) (Key Secondary Endpoint)
Временное ограничение: From date of randomization until date of death from any cause, assessed up to approx. 43 months
|
OS is defined as time to death for any cause |
From date of randomization until date of death from any cause, assessed up to approx. 43 months
|
|
Prostate-specific Antigen 90 (PSA90) Response
Временное ограничение: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)]
|
PSA90 response is defined as the proportion of patients who have a more/equal 90% decrease in PSA from baseline, it will be calculated at 12, 24 and 48 months. |
From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)]
|
|
Time to Development of mCRPC
Временное ограничение: From date of randomization till End Of Treatment (EOT) or death, which ever happen first, assessed up to 50 months (estimated final OS analysis)
|
Time to development of mCRPC is defined as the time from date of randomization to disease progression despite androgen deprivation therapy (ADT) presenting as either a continuous rise in serum prostate-specific antigen (PSA) levels, the progression of pre existing disease, and/or the appearance of new metastases. |
From date of randomization till End Of Treatment (EOT) or death, which ever happen first, assessed up to 50 months (estimated final OS analysis)
|
|
Progression Free Survival (PFS)
Временное ограничение: From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)
|
PFS is defined as the time from date of randomization to the date of first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) or death from any cause, whichever occurs first |
From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)
|
|
Second Progression Free Survival (PFS2)
Временное ограничение: From date of randomization until date of second progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)
|
PFS2 is defined as time from date of randomization to the first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) on next-line therapy or death from any cause, whichever occurs first. |
From date of randomization until date of second progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)
|
|
Change in Nadir Level of PSA Lower Than 0.2 ng/ml
Временное ограничение: From date of randomization till 30 days safety fup, whichever occur first, assessed up to 50 months (estimated final OS analysis)
|
Percentage of participants with PSA < 0.2 ng/mL at months 12, 24 and 48 months/ |
From date of randomization till 30 days safety fup, whichever occur first, assessed up to 50 months (estimated final OS analysis)
|
|
Time to Radiographic Soft Tissue Progression (TTSTP)
Временное ограничение: From date of randomization until date of soft tissue radiographic progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)
|
TTSTP is defined as time from randomization to radiographic soft tissue progression per PCWG3-modified RECIST v1.1 (Soft Tissue Rules of Prostate Cancer Working Group modified Response Evaluation Criteria in Solid Tumors Version 1.1) as assessed by Blinded Independent Central Review (BICR). |
From date of randomization until date of soft tissue radiographic progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)
|
|
Time to First Symptomatic Skeletal Event (SSE)
Временное ограничение: From date of randomization till EOT or death, whichever happens first, assessed up to 50 months (estimated final OS analysis)
|
Time to SSE (TTSSE) is defined as date of randomization to the date of first new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain or death from any cause, whichever occurs first. |
From date of randomization till EOT or death, whichever happens first, assessed up to 50 months (estimated final OS analysis)
|
|
Overall Response Rate (ORR)
Временное ограничение: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
|
ORR is defined as the proportion of participants with best overall response of complete response or partial response in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1. |
From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
|
|
Disease Control Rate (DCR)
Временное ограничение: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
|
DCR is defined as the proportion of participants with best overall response of complete response or partial response or Stable disease in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1. |
From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
|
|
Duration of Response (DOR)
Временное ограничение: From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)
|
DOR is defined as the duration of time between the date of first documented response (CR or PR) in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1, and the date of first documented progression or death due to any cause. |
From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)
|
|
Time to Response (TTR)
Временное ограничение: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
|
TTR is defined as the time from the date of randomization to the date of first documented response (CR or PR). |
From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
|
|
Functional Assessment of Cancer Therapy - Prostate (FACT-P) Questionnaire
Временное ограничение: From randomization up till 30 day safety Follow-up or week 48 of long term Follow-up for patients prematurely discontinued, assessed up to 50 months (estimated final OS analysis)
|
FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT-General + the Prostate Cancer Subscale (PCS). The FACT-General (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life. |
From randomization up till 30 day safety Follow-up or week 48 of long term Follow-up for patients prematurely discontinued, assessed up to 50 months (estimated final OS analysis)
|
|
Quality of Life ( EuroQoL) -5 Domain 5 Level Scale (EQ-5D-5L)
Временное ограничение: From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)
|
EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual. |
From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)
|
|
Brief Pain Inventory-short Form (PBI-SF)
Временное ограничение: From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)
|
The BPI-SF is a publicly available instrument to assess the pain and includes severity and interference scores. BPI-SF is an 11-item self report questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. Pain severity score is a mean value for BPI-SF questions 3, 4, 5 and 6 (questions inquiring about the extent of pain, where the extent is ranked from 0 [no pain] to 10 [pain as bad as you can imagine]). Pain severity progression is defined as an increase in score of 30% or greater from baseline without decrease in analgesic use. |
From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)
|
Соавторы и исследователи
Спонсор
Спонсор
Соавторы
Соавторы
Следователи
Следователи
- Директор по исследованиям: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Начало исследования
Первичное завершение (Действительный)
Первичное завершение
Завершение исследования (Оцененный)
Завершение исследования
Даты регистрации исследования
Первый отправленный
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Первый опубликованный
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее опубликованное обновление
Последнее отправленное обновление, отвечающее критериям контроля качества
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
- ПСМА
- 177Лу-ПСМА-617
- 68Ga-ПСМА-11
- Лютеций-177 ПСМА-617
- Терапия, направленная на андрогенные рецепторы
- АРДТ
- Терапия депривации андрогенов
- АТД
- Метастатический гормончувствительный рак предстательной железы
- mHSPC
- Выживаемость без рентгенологического прогрессирования
- рВБП
- Простатспецифический мембранный антиген
- Галлий-68 ПСМА-11
- Радиолигандная терапия
- РЛТ
Дополнительные соответствующие термины MeSH
- Урогенитальные заболевания
- Генитальные заболевания
- Генитальные новообразования, мужчины
- Урогенитальные новообразования
- Новообразования по локализации
- Новообразования
- Заболевания половых органов, мужчины
- Заболевания предстательной железы
- Мужские мочеполовые заболевания
- Новообразования предстательной железы
- Плювикто
- Галлий 68 PSMA-11
Другие идентификационные номера исследования
Другие идентификационные номера исследования
- CAAA617C12301
- 2023-507970-42-00 (Другой идентификатор: EU CTIS)
- 2023 (Грант/контракт NIH США)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Novartis is committed to sharing with qualified external researchers, access to participant-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .